Waycross Partners, LLC Biomarin Pharmaceutical Inc Transaction History

Waycross Partners, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 06, 2023	BUY	$80.93 - $108.63 $48,558 - $65,178	600 Added 9.38%	7,000 $724,000
Q4 2021 Feb 11, 2022	BUY	$71.72 - $91.47 $129,096 - $164,646	1,800 Added 39.13%	6,400 $565,000
Q2 2021 Aug 17, 2021	BUY	$75.51 - $84.79 $143,469 - $161,101	1,900 Added 70.37%	4,600 $384,000
Q2 2021 Aug 13, 2021	SELL	$75.51 - $84.79 $143,469 - $161,101	-1,900 Reduced 41.3%	2,700 $1.29 Million
Q4 2020 Feb 08, 2021	BUY	$72.61 - $90.2 $334,006 - $414,920	4,600 New	4,600 $403,000

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Waycross Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Waycross Partners, LLC with notifications on news.